GlassScriptPhysician profile
James L Maliszewski
NPI 1205197464
$314.94
in general payments reported to CMS, 2019-2025
13 companies · $36.36 in 2025
The $36.36 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.17 · 2022: $76.08 · 2023: $144 · 2024: $43.42 · 2025: $36.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $223.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $62.18 | 2024-2025 | Watchman Flx |
| Pfizer INC. | $57.44 | 2022-2025 | |
| Lilly USA, LLC | $29.55 | 2021-2023 | Mounjaro |
| Sumitomo Pharma America, INC. | $26.57 | 2023 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $17.51 | 2022 | |
| Abbvie INC. | $17.48 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.83 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $15.23 | 2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $15.20 | 2023 | Fasenra |
| Xeris Pharmaceuticals, INC. | $14.99 | 2023 | Gvoke Hypopen |
| Dexcom, INC. | $14.86 | 2022 | |
| Novo Nordisk INC | $14.44 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.66 | 2023 | Jardiance, Synjardy, Tradjenta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Maliszewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.